Cary Street Partners Financial LLC Trims Stake in Zimmer Biomet Holdings, Inc. $ZBH

Cary Street Partners Financial LLC lowered its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 76.7% in the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,882 shares of the medical equipment provider’s stock after selling 6,203 shares during the period. Cary Street Partners Financial LLC’s holdings in Zimmer Biomet were worth $185,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in ZBH. Key Financial Inc raised its holdings in Zimmer Biomet by 164.6% in the third quarter. Key Financial Inc now owns 262 shares of the medical equipment provider’s stock worth $26,000 after purchasing an additional 163 shares in the last quarter. Cullen Frost Bankers Inc. grew its position in shares of Zimmer Biomet by 66.7% in the 3rd quarter. Cullen Frost Bankers Inc. now owns 290 shares of the medical equipment provider’s stock worth $29,000 after buying an additional 116 shares during the period. Cary Street Partners Investment Advisory LLC increased its stake in shares of Zimmer Biomet by 83.7% in the 2nd quarter. Cary Street Partners Investment Advisory LLC now owns 327 shares of the medical equipment provider’s stock worth $30,000 after acquiring an additional 149 shares in the last quarter. Root Financial Partners LLC purchased a new position in Zimmer Biomet during the 3rd quarter valued at about $31,000. Finally, Mather Group LLC. bought a new stake in Zimmer Biomet during the third quarter worth about $36,000. 88.89% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the stock. Canaccord Genuity Group lowered their target price on shares of Zimmer Biomet from $101.00 to $93.00 and set a “hold” rating for the company in a report on Monday, November 10th. Robert W. Baird reiterated a “neutral” rating and set a $100.00 price objective (down from $117.00) on shares of Zimmer Biomet in a research note on Tuesday, December 16th. The Goldman Sachs Group downgraded Zimmer Biomet from a “neutral” rating to a “sell” rating and set a $93.00 target price on the stock. in a report on Friday, January 9th. Weiss Ratings restated a “hold (c-)” rating on shares of Zimmer Biomet in a report on Wednesday, January 21st. Finally, UBS Group reiterated a “sell” rating and issued a $89.00 price target on shares of Zimmer Biomet in a research note on Wednesday, February 11th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, ten have issued a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat, Zimmer Biomet has an average rating of “Hold” and a consensus target price of $106.20.

Zimmer Biomet Stock Performance

Shares of NYSE ZBH opened at $98.42 on Monday. The firm’s 50-day moving average price is $91.52 and its 200-day moving average price is $95.86. Zimmer Biomet Holdings, Inc. has a 52-week low of $84.59 and a 52-week high of $114.44. The company has a market cap of $19.25 billion, a PE ratio of 27.80, a PEG ratio of 2.01 and a beta of 0.58. The company has a quick ratio of 1.10, a current ratio of 1.98 and a debt-to-equity ratio of 0.55.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings data on Tuesday, February 10th. The medical equipment provider reported $2.42 earnings per share for the quarter, beating the consensus estimate of $2.38 by $0.04. Zimmer Biomet had a net margin of 8.56% and a return on equity of 12.93%. The firm had revenue of $2.24 billion during the quarter, compared to analysts’ expectations of $2.22 billion. During the same period in the previous year, the company earned $2.31 earnings per share. The firm’s quarterly revenue was up 10.9% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. As a group, analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, April 30th. Investors of record on Tuesday, March 31st will be issued a $0.24 dividend. The ex-dividend date of this dividend is Tuesday, March 31st. This represents a $0.96 annualized dividend and a dividend yield of 1.0%. Zimmer Biomet’s payout ratio is presently 27.12%.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.